Press Releases

2013

April 2, 2013
SuppreMol appoints industry expert Klaus Schollmeier as CEO

2012

December 10, 2012
SuppreMol’s SM101 shows a sustained clinical activity and a favorable safety profile in Primary Immune Thrombocytopenia (ITP) patients
November 7, 2012
SuppreMol announces presentation of clinical data for its lead product SM101 at the 54th ASH Annual Meeting
July 24, 2012
SuppreMol begins development of Anti-IL-3 monoclonal antibody to  diagnose and treat early stage Rheumatoid Arthritis
February 14, 2012
SuppreMol releases positive interim Phase Ib/IIa results on SM101 in Primary Immune Thrombocytopenia (ITP) trials

2011

November 28, 2011
SuppreMol starts SM101 dosing in the context of SMILE study
August 2, 2011
SuppreMol employs Protagen biomarkers in SLE study.
July 11, 2011
SuppreMol initiates Phase IIa clinical trial in Systemic Lupus Erythematosus (SLE) with its lead candidate SM101
May 17, 2011
SuppreMol obtains option to in-license antibody against interleukin 3 (IL-3)
January 24, 2011
SuppreMol Completes Successful Pre-IND Meeting with FDA

2010

December 6, 2010
SuppreMol receives public research funding to advance its lead project SM101 into SLE as further indication
December 1, 2010
SuppreMol Closes EUR 15.5 M Series C Financing Round
April 19, 2010
SuppreMol Receives U.S. Orphan Drug Designation for SM101
April 12, 2010
SuppreMol initiates Phase Ib/IIa clinical trial with its lead candidate SM101
February 8, 2010
SuppreMol appoints Dr. Robert Phelps as Head of Business Development & Licensing